Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE

  1. Mateos, M.-V.
  2. Dimopoulos, M.A.
  3. Cavo, M.
  4. Suzuki, K.
  5. Knop, S.
  6. Doyen, C.
  7. Lucio, P.
  8. Nagy, Z.
  9. Pour, L.
  10. Grosicki, S.
  11. Crepaldi, A.
  12. Liberati, A.M.
  13. Campbell, P.
  14. Yoon, S.-S.
  15. Iosava, G.
  16. Fujisaki, T.
  17. Garg, M.
  18. Iida, S.
  19. Bladé, J.
  20. Ukropec, J.
  21. Pei, H.
  22. Van Rampelbergh, R.
  23. Kudva, A.
  24. Qi, M.
  25. San-Miguel, J.
Aldizkaria:
Clinical Lymphoma, Myeloma and Leukemia

ISSN: 2152-2669,  2152-2650

Argitalpen urtea: 2021

Alea: 21

Zenbakia: 11

Orrialdeak: 785-798

Mota: Artikulua

DOI: 10.1016/J.CLML.2021.06.005 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus